Vaccine for deadly virus with ‘pandemic potential’ gets funding boost

• A vaccine for the deadly Nipah virus, developed by the University of Oxford, may soon be available to patients.
• The vaccine has been granted support from the European Medicines Agency's Prime scheme to fast-track treatment delivery.
• The World Health Organisation considers Nipah a research priority due to its pandemic potential and high fatality rate (up to 85%).
• Nipah can transmit to humans via animals, contaminated foods, or directly from person to person, causing symptoms like fever and potentially fatal brain swelling.
• The University of Oxford is currently conducting phase 1 testing of its Nipah jab after promising early results, with the EMA noting the increasing risk of Nipah virus transmission due to human encounters with fruit bats.

IN FULL

Vaccine fast-tracked for virus that kills up to 85% of people it infects